
A groundbreaking targeted treatment for the most common type of bladder cancer has been approved for use by the NHS, offering new hope to hundreds of patients.
The National Institute of Health and Care Excellence (Nice) has recommended erdafitinib, also known as Balversa and manufactured by Johnson & Johnson, for some adult patients in England. This decision is expected to benefit about 420 individuals.